New drug TALZENNA tested for Tough-to-Treat breast cancer
NCT ID NCT06735742
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at the safety of the drug TALZENNA in people with a specific type of breast cancer (BRCA mutation-positive, HER2-negative) that cannot be surgically removed or has come back after previous chemotherapy. Only 3 participants who have not used TALZENNA before will receive the drug as prescribed and be followed for up to 12 months. The main goal is to track any side effects, especially those affecting the bone marrow, lungs, blood vessels, or causing new tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRCA MUTATION-POSITIVE AND HER2-NEGATIVE UNRESECTABLE OR RECURRENT BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pfizer Japan
Tokyo, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?